iOrganBio, Inc. is a venture capital-backed biotechnology startup founded in 2024 and headquartered in Chapel Hill, North Carolina, United States. The company specializes in the development of advanced platforms for the design and manufacturing of human cells and organoids.
Its flagship technology, CellForge™, is an AI-powered system that combines artificial intelligence prediction, biological sensing, robotics, and automated 3D incubation to enable precise, reproducible, and scalable production of human cells. This closed-loop autonomous laboratory approach supports applications in drug discovery, disease modeling, regenerative medicine, and cell therapies by providing consistent cell models that replicate in-vivo human biology.
The platform is complemented by CellAtlas™, a comprehensive database of digital profiles derived from single-cell and multi-omics data of adult human cells and tissues. iOrganBio aims to accelerate the shift toward human-relevant in vitro models as alternatives to traditional animal testing.
The company emerged from stealth mode in October 2025 following a $2 million seed financing round led by First Star Ventures, with participation from investors including IndieBio, Cape Fear BioCapital, 2ndF, Terasaki Institute, and Alix Ventures. In late 2026, Mitsui Chemicals invested in the company through its corporate venture capital fund 321Catalyst™. iOrganBio operates as a privately held entity with approximately 17 employees and maintains its primary operations in the United States.
Also known as iOrgan Bio, Inc..
None yet. When a new project in the record names iOrganBio as owner, partner or investor, it shows here.
Links Mitsui's materials and InnoCell plates with an AI-driven closed-loop platform to improve uniformity and manufacture of human cells and organoids for drug discovery and regenerative medicine.
